Keith Drake

Greylock McKinnon Associates

Keith M. Drake is a Director at Greylock McKinnon Associates, an economic consulting firm, and a Professor of the Practice at the Geisel School of Medicine at Dartmouth.

His consulting work and academic research focus on competition in the pharmaceutical industry, including brand-generic dynamics, "pay-for-delay" patent settlements, authorized generics, and the timing of biosimilar and generic entry. His research has been cited in federal antitrust rulings, and a co-authored paper on reverse-payment settlements won the best paper prize from the International Journal of the Economics of Business in 2016.

Policy Briefs

1.3%-5.3%

of Spending on Small Molecule Drugs

(0.06%-0.23% of Total Health Spending)

Prescription Drugs

Keith Drake

Keith M. Drake is a Director at Greylock McKinnon Associates, an economic consulting firm, and a Professor of the Practice at the Geisel School of Medicine at Dartmouth.

Policy Briefs

1.3%-5.3%

Ending Pay-for-Delay Patent Litigation Settlements in the Pharmaceutical Industry

Evidence-based steps for health care reform.

Keith M. Drake is a Director at Greylock McKinnon Associates, an economic consulting firm, and a Professor of the Practice at the Geisel School of Medicine at Dartmouth.

Policy Briefs

1.3%-5.3%

Ending Pay-for-Delay Patent Litigation Settlements in the Pharmaceutical Industry

Join Our Mailing List